{"id":"four-weekly-tc-consolidation-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Neuropathy"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1738872","moleculeType":"Small molecule","molecularWeight":"439.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TC (paclitaxel/carboplatin) is a standard chemotherapy doublet where paclitaxel stabilizes microtubules to disrupt cell division and carboplatin cross-links DNA to induce apoptosis. The four-weekly consolidation schedule delivers these agents at extended intervals following initial therapy to target remaining malignant cells while allowing recovery between cycles.","oneSentence":"Four-weekly TC consolidation chemotherapy combines paclitaxel and carboplatin administered on an extended schedule to eliminate residual cancer cells after initial treatment.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:13:21.362Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Consolidation therapy in advanced or metastatic cancer (specific indication not specified in available data)"}]},"trialDetails":[{"nctId":"NCT07306663","phase":"PHASE3","title":"Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2021-06-01","conditions":"Esophageal Cancer","enrollment":242}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Four-Weekly TC Consolidation Chemotherapy","genericName":"Four-Weekly TC Consolidation Chemotherapy","companyName":"Jiangsu Cancer Institute & Hospital","companyId":"jiangsu-cancer-institute-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Four-weekly TC consolidation chemotherapy combines paclitaxel and carboplatin administered on an extended schedule to eliminate residual cancer cells after initial treatment. Used for Consolidation therapy in advanced or metastatic cancer (specific indication not specified in available data).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}